AbCellera Biologics Change in Accounts Payable 2019-2025 | ABCL

AbCellera Biologics change in accounts payable from 2019 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.

AbCellera Biologics Change in Accounts Payable 2019-2025 | ABCL

AbCellera Biologics change in accounts payable from 2019 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$228.3B
Amgen (AMGN)$153.1B
Gilead Sciences (GILD)$137.2B
Vertex Pharmaceuticals (VRTX)$99B
Bristol Myers Squibb (BMY)$91.2B
CSL (CSLLY)$84.8B
GSK (GSK)$75B
Regeneron Pharmaceuticals (REGN)$59.9B
Alnylam Pharmaceuticals (ALNY)$56.1B
Argenex SE (ARGX)$41.2B
BioNTech SE (BNTX)$26.8B
Insmed (INSM)$21.1B
Royalty Pharma (RPRX)$20.9B
Biogen (BIIB)$19B
Incyte (INCY)$15.2B
Illumina (ILMN)$14.5B
Genmab (GNMSF)$14.3B
Genmab (GMAB)$13.8B
BioMarin Pharmaceutical (BMRN)$11.6B
Ascendis Pharma (ASND)$11.2B
Swedish Orphan Biovitrum (BIOVF)$10.6B
QIAGEN (QGEN)$10.6B
Moderna (MRNA)$10.4B
Exelixis (EXEL)$10.2B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.8B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.9B
Bio-Techne Corp (TECH)$7.8B
Halozyme Therapeutics (HALO)$7.7B